Bioglutide (also known as NA-931) is an experimental research product developed for the treatment of obesity and type 2 diabetes.
It functions as a first-in-class quadruple receptor agonist that stimulates:
GLP-1 + GIP + GLUCAGON
and IGF-1 receptors. Researched to eliminate, minimize muscle wasting in a calorie deficit state. Another critical feature that advances weight management research ahead of all other previous products.